Erlotinib (Erl)
Erlotinib is an EGFR inhibitor. The drug follows Iressa (gefitinib), which was the first drug of this type. Erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is highly expressed and occasionally mutated in various forms of cancer. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. By inhibiting the ATP, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Erlotinib (Erl) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Erlotinib (Erl) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Erlotinib (Erl) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Erlotinib (Erl) CLIA Kit Customized Service Offer
n/a ELISA Kit for Erlotinib (Erl) ELISA Kit Customized Service Offer